Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Alnylam Pharmaceuticals will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PT [1] - The company plans to unveil its new five-year strategy aimed at guiding its next phase of growth [1] - An update on unaudited fourth quarter and full year 2025 global net product revenues will be shared, along with an outlook for 2026 product sales [1] Company Overview - Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, focusing on innovative medicines for rare and prevalent diseases with unmet needs [2] - The company has developed commercial RNAi therapeutic products including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, and collaborates with partners like Novartis and Sanofi for additional products [2] - Alnylam has a robust pipeline of investigational medicines, with multiple candidates in late-stage development [2] Strategic Vision - The company is executing its "5Alnylam Px25" strategy to deliver transformative medicines for both rare and common diseases [2] - Alnylam aims to benefit patients globally through sustainable innovation and exceptional financial performance, establishing a leading profile in the biotech industry [2]